Myriad Genetic Laboratories, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$3.6Mgeneral payments (2019-2025)
$16Kresearch payments (2019-2025)
14,205clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Myrisk $993K associated (2023-2025)
- Prolaris $665K associated (2023-2025)
- Precisetumor $317K associated (2023-2025)
- Mychoice Cdx $53K associated (2023-2025)
- Bracanalysis Cdx $15K associated (2023-2025)
- Genesight $5,000 associated (2023-2025)
- Endopredict $1,914 associated (2023-2025)
- Colaris $1,115 associated (2023-2025)
- Bracanalysis $1,041 associated (2023-2025)
- Colaris Ap $898 associated (2023-2025)
- Risk Score $284 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Adam Cole | Little Rock, AR | Anatomic Pathology & Clinical Pathology | $207,669.19 |
| Adam Brufsky | Pittsburgh, PA | $192,639.70 | |
| Devesh Pandya | Houston, TX | Hematology & Oncology | $118,007.11 |
| Sharyn Lewin | Teaneck, NJ | Gynecologic Oncology | $115,872.31 |
| Alfredo Santillan Gomez | San Antonio, TX | Surgical Oncology | $105,126.59 |
| Sucharu Prakash | Paris, TX | Medical Oncology | $93,236.43 |
| Bradley Monk | West Palm Beach, FL | Gynecologic Oncology | $82,234.92 |
| Christopher Lee | Spokane Valley, WA | Radiation Oncology | $63,066.86 |
| Candace Westgate | Indianapolis, IN | Obstetrics & Gynecology | $60,551.71 |
| Antonio Santillan-Gomez | San Antonio, TX | Gynecologic Oncology | $58,390.92 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.